Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Returns
Return on equity-31%+25.3pp-36.9%+45.3pp-42.1%-63.2%-56.3%
Return on assets-30.1%+23.6pp-35.6%+42.1pp-39.5%+16.7pp-58.3%-53.7%
Liquidity
Current ratio44.3×+17.8×43.8×+29.7×25.5×+17.0×15.1×+3.9×26.5×+8.4×
Quick ratio44.3×+17.8×43.8×+29.7×25.5×+17.0×15.1×+3.9×26.5×+8.4×
Cash ratio0.1×0.0×0.1×0.0×0.1×0.0×0.0×0.1×-0.2×
Leverage
Interest coverage-8.7×+6.8×-10.7×+2.5×-14.5×-3.3×-16.5×-7.4×-15.5×-8.2×
Per Share
Book value per share$7.70+19.9%$9.56+143%$8.17+71.7%$4.79-18.5%$6.42-12.1%
Valuation
Market capitalization$2.23B+124%$2.87B+369%$2.94B+392%$921.58M+75.4%$997.24M+92.7%
Price / book3.5×+0.6×4.4×+1.2×5.1×+2.6×2.9×+1.1×2.9×+1.3×
Earnings yield-6.8%+12.1pp-5.4%+23.6pp-5.8%+19.8pp-20.7%+2.1pp-18.9%-1.4pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Mineralys Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Mineralys Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.